Cargando…

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma

Clinical development of chimeric antigen receptor (CAR)-T-cell therapy has been enabled by advances in synthetic biology, genetic engineering, clinical-grade manufacturing, and complex logistics to distribute the drug product to treatment sites. A key ambition of the CARAMBA project is to provide cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prommersberger, Sabrina, Reiser, Michael, Beckmann, Julia, Danhof, Sophia, Amberger, Maximilian, Quade-Lyssy, Patricia, Einsele, Hermann, Hudecek, Michael, Bonig, Halvard, Ivics, Zoltán
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455317/ https://www.ncbi.nlm.nih.gov/pubmed/33846552 http://dx.doi.org/10.1038/s41434-021-00254-w

Ejemplares similares

P808: CONTROLLED FRATRICIDE TO AUGMENT ANTI-MYELOMA REACTIVITY OF SLAMF7 AND CD38 CAR T CELLS
por: Konetzki, Verena, et al.
Publicado: (2023)

P836: ANTIBODY-DRUG CONJUGATES AS POTENTIAL CAR-T CELL SPECIFIC OFF-SWITCH IN MULTIPLE MYELOMA
por: Bielowski, Anna, et al.
Publicado: (2023)

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
por: Danhof, Sophia, et al.
Publicado: (2021)

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
por: Rodríguez-Lobato, Luis Gerardo, et al.
Publicado: (2020)

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
por: Einsele, Hermann, et al.
Publicado: (2016)

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
por: Nerreter, Thomas, et al.
Publicado: (2019)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells
por: García-Guerrero, Estefanía, et al.
Publicado: (2022)

A highly soluble Sleeping Beauty transposase improves control of gene insertion
por: Querques, Irma, et al.
Publicado: (2019)

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
por: Zhou, Xiang, et al.
Publicado: (2020)

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma
por: Merker, Michael, et al.
Publicado: (2020)

Chemical Composition, In vivo Digestibility and Metabolizable Energy Values of Caramba (Lolium multiflorum cv. caramba) Fresh, Silage and Hay
por: Özelçam, H., et al.
Publicado: (2015)

Caramba y zamba la cosa : el 68 vuelto a contar /
por: Pérez Arce, Francisco
Publicado: (2017)

Contemporary Transposon Tools: A Review and Guide through Mechanisms and Applications of Sleeping Beauty, piggyBac and Tol2 for Genome Engineering
por: Sandoval-Villegas, Nicolás, et al.
Publicado: (2021)

Immuntherapien zur Behandlung der chronischen Hepatitis-B-Virusinfektion – eine Übersicht unter besonderer Berücksichtigung von CAR-T-Zellen
por: Ivics, Zoltan, et al.
Publicado: (2020)

Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

CAR-T-Zell-Therapie beim multiplen Myelom
por: Zhou, X., et al.
Publicado: (2021)

Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia
por: Maucher, Marius, et al.
Publicado: (2021)

Negative Regulation of Humoral Immunity Due to Interplay between the SLAMF1, SLAMF5, and SLAMF6 Receptors
por: Wang, Ninghai, et al.
Publicado: (2015)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

Clinical impact of serum soluble SLAMF7 in multiple myeloma
por: Ishibashi, Mariko, et al.
Publicado: (2018)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
por: Chu, Emily, et al.
Publicado: (2023)

Automatic generation of alloreactivity-reduced donor lymphocytes and hematopoietic stem cells from the same mobilized apheresis product
por: Wiercinska, E., et al.
Publicado: (2023)

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
por: García-Guerrero, Estefanía, et al.
Publicado: (2020)

Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
por: García-Guerrero, Estefanía, et al.
Publicado: (2021)

Jumping Ahead with Sleeping Beauty: Mechanistic Insights into Cut-and-Paste Transposition
por: Ochmann, Matthias T., et al.
Publicado: (2021)

CAR-T-Zell-basierte Immuntherapien in der Hämatoonkologie: Fokus auf den Einsatz in der klinischen Routine
por: Steinhardt, M. J., et al.
Publicado: (2023)

CRISPR-Mediated Triple Knockout of SLAMF1, SLAMF5 and SLAMF6 Supports Positive Signaling Roles in NKT Cell Development
por: Huang, Bonnie, et al.
Publicado: (2016)

Long-Term Disease Control by Pomalidomide-/Dexamethasone-Based Therapy in a Patient with Advanced Multiple Myeloma: A Case Report and Review of the Literature
por: Danhof, Sophia, et al.
Publicado: (2015)

CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells
por: O’Neal, Julie, et al.
Publicado: (2022)

CRISISS: A Novel, Transcriptionally and Post-Translationally Inducible CRISPR/Cas9-Based Cellular Suicide Switch
por: Amberger, Maximilian, et al.
Publicado: (2023)

RNA-guided retargeting of Sleeping Beauty transposition in human cells
por: Kovač, Adrian, et al.
Publicado: (2020)

Migration of Myeloid Cells during Inflammation Is Differentially Regulated by the Cell Surface Receptors Slamf1 and Slamf8
por: Wang, Guoxing, et al.
Publicado: (2015)

Sleeping Beauty Transposon Insertions into Nucleolar DNA by an Engineered Transposase Localized in the Nucleolus
por: Kovač, Adrian, et al.
Publicado: (2023)

The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study
por: Fischer, Julia, et al.
Publicado: (2022)

Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors
por: Holstein, Marta, et al.
Publicado: (2018)

Responses to Microbial Challenges by SLAMF Receptors
por: van Driel, Boaz Job, et al.
Publicado: (2016)

Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer
por: Stüber, Tanja, et al.
Publicado: (2020)

SLAMF6 clustering is required to augment T cell activation
por: Dragovich, Matthew A., et al.
Publicado: (2019)

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
por: Campbell, Kerry S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2cah9p8f9k44758bq40696lteq